CSF2 and pancreatic ductal adenocarcinoma: This finding aligns with evidence reported in other tumors, such as mesothelioma and pancreatic ductal adenocarcinoma, where the blockade of GM-CSF with a neutralizing antibody significantly attenuated the immunosuppressive potential of myeloid cells, leading to restored T-cell proliferation and activity [12,25].